Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Oric Pharmaceuticals (ORIC) EPS (Weighted Average and Diluted) (2021 - 2026)

Oric Pharmaceuticals filings provide 6 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.34 for Q1 2026.

  • Quarterly EPS (Weighted Average and Diluted) rose 19.05% to -$0.34 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$1.41 through Mar 2026, up 24.6% year-over-year, with the annual reading at -$1.47 for FY2025, 19.67% up from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.34 in Q1 2026 for Oric Pharmaceuticals, down from -$0.27 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.27 in Q4 2025 and bottomed at -$0.63 in Q3 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.46, with a median of -$0.49 recorded in 2024.
  • The largest annual shift saw EPS (Weighted Average and Diluted) plummeted 34.04% in 2022 before it skyrocketed 47.06% in 2025.
  • Oric Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.52 in 2022, then increased by 3.85% to -$0.5 in 2023, then dropped by 2.0% to -$0.51 in 2024, then skyrocketed by 47.06% to -$0.27 in 2025, then fell by 25.93% to -$0.34 in 2026.
  • Per Business Quant, the three most recent readings for ORIC's EPS (Weighted Average and Diluted) are -$0.34 (Q1 2026), -$0.27 (Q4 2025), and -$0.33 (Q3 2025).